Inspire Medical Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Inspire Upper Airway Stimulation (UAS) therapy for use in a subset of patients with moderate to severe Obstructive Sleep Apnea (OSA) who are unable to use Continuous Positive Airway Pressure (CPAP). Inspire therapy is a fully implanted neurostimulation device, the first of its kind for sleep apnea, that provides an alternative treatment that is proven, convenient and easy to use.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/7169651-fda-approves-inspire-upper-airway-stimulation-therapy-sleep-apnea
Northwestern Medicine’s Bluhm Cardiovascular Institute is celebrating the success of its transcatheter valve program, a pioneering technology that replaces or repairs leaky heart valves without open-heart surgery. On August 25, 2016, more than 50 former transcatheter valve replacement patients and their family members celebrated the life-saving procedure that has extended both their lives and their ability to enjoy them.
The Bluhm Cardiovascular Institute hit the milestone of being the first hospital in Illinois to perform the 500th TAVR, or transcatheter aortic valve replacement, since the program’s inception in 2008. Charles J. Davidson, MD, performed the 500th procedure on July 23, 2016.
To view the multimedia release go to:
http://www.multivu.com/players/English/7049452-northwestern-medicine-transcatheter-valve/
According to a recent survey, active adults aren’t slowing down. The survey found that 62 percent of adults ages 30-49 continue to work out as much – and with the same or more intensity – as they did in their 20s. More than half would like to ramp up their performance and do more of what they love, but are stopped by pain and the risk of injuries.
Massage Envy’s new, proprietary assisted stretching service, called Total Body Stretch, is designed to help people perform at their best, ease the muscle pain and tension that comes with activity, and resist injuries.
Developed for Massage Envy by an acclaimed chiropractor, massage therapist and ergonomist and performed by a stretching professional, the Total Body Stretch service is built around the company’s proprietary Streto Method, a sequence of 10 targeted stretches designed to increase flexibility, mobility and performance.
To view the multimedia release go to:
https://www.multivu.com/players/English/8133351-massage-envy-streto-total-body-stretch/
EnteroMedics Inc. (NASDAQ: ETRM) today announced that the U.S. Food and Drug Administration (FDA) has approved VBLOC® vagal blocking therapy, delivered via the Maestro® System, for the treatment of adult patients with obesity who have a Body Mass Index (BMI) of at least 40 to 45 kg/m2, or a BMI of at least 35 to 39.9 kg/m2 with a related health condition such as high blood pressure or high cholesterol levels, and who have tried to lose weight in a supervised weight management program within the past five years. The Maestro System is the first new medical device to be approved by the FDA for obesity in over ten years. EnteroMedics anticipates that the device will be available, on a limited basis, at select Bariatric Centers of Excellence in the U.S. this year. The Maestro System has received CE Mark and is listed on the Australian Register of Therapeutic Goods.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7269351-enteromedics-fda-approval-vbloc-maestro-system-weight-loss-device/
Let’s Win, an initiative supported by the Lustgarten Foundation, launched the Let’s Win! Pancreatic Cancer Survivors video series Friday, January 19, 2018, at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium. The new online video series, featuring long-term pancreatic cancer survivors of all ages and diverse backgrounds, has been created to show pancreatic cancer patients and their families that people do survive this disease. The survivors have responded exceptionally well to pancreatic cancer therapy that incorporates clinical trials and treatments that go beyond traditional protocols.
When patients are first diagnosed with pancreatic cancer, they often turn to the internet, only to find devastating and frightening statistics about the disease. “Our goal is to provide hope and inspiration to patients and their families,” says Cindy Gavin, founding executive director of Let’s Win. “We are so grateful for the incredible vision of one special patient and the generosity of The Flora Family Foundation for their support of this incredible initiative.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8213752-lets-win-pancreatic-cancer-survivor-video-series/
Forget all your worries and refresh your mood with relaxing music and get peaceful sleep with sleep music here. Try our soothing music and experience its magic.http://www.easysleepmusic.com
University of St. Augustine for Health Sciences (USAHS), a leading graduate institution that emphasizes health and rehabilitative sciences education through innovative classroom education, is pleased to announce the installation of SafeGait 360° Balance and Mobility Trainer® on its Austin, Texas campus. The device, which was designed in collaboration with experts in physical therapy (PT) and occupational therapy (OT), works to mitigate the risk of injury from falls, protecting both the patient and therapist. In addition, SafeGait 360°’s dynamic fall protection (DFP) distinguishes between a patient’s intentional downward movement and when a patient is actually falling, which allows therapists to easily modify fall protection sensitivity to accommodate and challenge patients at varying stages of independence.
USAHS is one of the first higher education institutions in the nation to install this innovative body-weight support and fall protection system. In addition to conducting ground breaking research with patients and students, faculty members with extensive experience in body-weight treatments aim to open a clinic which will provide new treatment options to patients in the Austin community, and will begin seeing patients in October of this year.
To view the multimedia release go to:
http://www.multivu.com/players/English/7743851-usahs-safegait-360-physical-therapy/
Oro Valley Audiology
2542 E Vistoso Commerce Loop Rd, Tucson, AZ 85755, USA
(520) 825-4770
http://hearintucson.com
https://www.google.com/maps?cid=7471816986561274177
https://www.google.com/search?q=Oro+Valley+Audiology&kponly&kgmid=/g/1thx4hd3
As the name suggests, and audiologist is a health-care professional who concentrates on the medical diagnoses, recognition, tracking and treatment of conditions of the auditory and vestibular parts of the ear. These specialists dispense hearing aids, manage and fix up hearing problems and evaluate candidacy for cochlear implants. An audiologist helps style and carry out individual and industrial hearing safety programs, newborn hearing screening programs, and school hearing screening programs.
Audiologists have training in anatomy and physiology, hearing aids, cochlear implants, electrophysiology, acoustics, psychophysics, neurology, vestibular function and evaluation, balance disorders, therapy and indication language. Unfortunately, hearing loss is prevalent throughout the U.S.
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
Changes in the treatment of pediatric cancer over recent decades have translated to a reduced risk of serious, long-term late health effects of cancer therapy. This is according to the latest analysis from the Childhood Cancer Survivor Study (CCSS), a National Cancer Institute-funded resource for late-effects research, led by investigators at St. Jude Children’s Research Hospital.
“This is the first comprehensive study to demonstrate how changes in treatments over time have impacted the occurrence of late effects experienced by childhood cancer survivors,” said Todd Gibson, Ph.D., assistant member of the Department of Epidemiology and Cancer Control at St. Jude. “We found the 15-year cumulative incidence of people reporting at least one severe health condition decreased from 12.7 percent among childhood cancer survivors diagnosed in the 1970s to 10.1 percent for those diagnosed in the 1980s to 8.8 percent in the 1990s–a statistically significant decline.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7924756-st-jude-childhood-cancer-survivorship-asco-2017/
A first-of-a-kind neural stem cell therapy that works with a common cold virus to seek out and attack a lethal and aggressive brain cancer is being tested at Northwestern Medicine in a Phase I clinical trial for patients newly diagnosed with malignant glioma.
The novel drug to treat malignant glioma, notorious for recurring after typical bouts of standard cancer treatment, was developed by a Northwestern scientist and has been approved as an investigational drug by the U.S. Food and Drug Administration. This is only the second time the University has supported and filed an investigational new drug as a sponsor.
To view the multimedia release go to:
https://www.multivu.com/players/English/7944251-northwestern-medicine-stem-cell-trial/
Adolescents and young adults with a severe inherited immunodeficiency disorder improved following treatment with novel gene therapy developed at St. Jude Children’s Research Hospital and at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The results of this study appear today in the journal Science Translational Medicine.
The study involved five males with X-linked severe combined immunodeficiency disease (SCID-X1), also known as “Bubble Boy” disease, who were all treated at NIAID. This inherited disorder involves a mutation in the IL2RG gene that affects males and occurs in 1 of every 50,000 to 100,000 live births, leaving them with little to no immune protection.
To view the multimedia release go to:
http://www.multivu.com/players/English/7808651-st-jude-gene-therapy-results/
